Search - tctmd.com

Displaying 201 - 220 of 972

Sort: Relevancy | Date

News Daily News

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

Michael O'Riordan

December 08, 2023

News Daily News

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

Caitlin E. Cox

December 06, 2023

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Opinion CV Team Dispatch

December 2023 Dispatch for the CV Team

L.A. McKeown

December 01, 2023

News Daily News

Turning Back Subclinical Atherosclerosis Possible in Some Middle-Age People

Todd Neale

November 22, 2023

News Daily News

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

L.A. McKeown

November 20, 2023

News Conference News AHA 2023

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

Todd Neale

November 17, 2023

Presentation AHA 2023

Physician Optimised Postpartum Hypertension Treatment (POP-HT) Randomised Trial

Presenter: Jamie Kitt

November 17, 2023

News Conference News AHA 2023

Novel AI-Guided CV Risk Prediction Takes Aim at Coronary Inflammation

L.A. McKeown

November 17, 2023

News Conference News AHA 2023

AI Improves Detection of Cardiomyopathy in Pregnancy

L.A. McKeown

November 15, 2023

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

Presentation AHA 2023

Screening For Peripartum Cardiomyopathies Using An AI-Enhanced Digital Stethoscope: A Randomized Clinical Trial

Presenter: Demilade Adedinsewo

November 13, 2023

News Conference News AHA 2023

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

L.A. McKeown

November 13, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

L.A. McKeown

November 12, 2023

News Conference News AHA 2023

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Caitlin E. Cox

November 12, 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP-Lowering KARDIA-1

News Conference News AHA 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

Caitlin E. Cox

November 11, 2023

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Caitlin E. Cox

November 07, 2023

News Daily News

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

Yael L. Maxwell

October 19, 2023

News Conference News HFSA 2023

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

L.A. McKeown

October 18, 2023

Advertisement

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

December 2023 Dispatch for the CV Team

Turning Back Subclinical Atherosclerosis Possible in Some Middle-Age People

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

Physician Optimised Postpartum Hypertension Treatment (POP-HT) Randomised Trial

Novel AI-Guided CV Risk Prediction Takes Aim at Coronary Inflammation

AI Improves Detection of Cardiomyopathy in Pregnancy

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Screening For Peripartum Cardiomyopathies Using An AI-Enhanced Digital Stethoscope: A Randomized Clinical Trial

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content